Merus NV (NASDAQ:MRUS)
| 13.44 Delayed Data As of 3:59pm ET |  -0.02 / -0.15%Today’s Change | 10.19 Today|||52-Week Range 20.95 | -4.55% Year-to-Date |
Latest MRUS News | Press Releases
| Merus nabs US Orphan Drug tag for Zeno in pancreatic cancer Jul 27 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 13.46 |
| Today’s open | 13.51 |
| Day’s range | 13.16 - 13.51 |
| Volume | 1,253 |
| Average volume (3 months) | 132,740 |
| Market cap | $396.4M |
Data as of 3:59pm ET, 08/05/2020
Growth & Valuation
| Earnings growth (last year) | -77.26% |
| Earnings growth (this year) | -6.61% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -15.56% |
| P/E ratio | NM |
| Price/Sales | 10.95 |
| Price/Book | 3.00 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PDLIPDL BioPharma Inc | -0.09 | -2.62% |
| APTOAptose Biosciences I... | +0.20 | +3.89% |
| KMDAKamada Ltd | +0.08 | +0.90% |
| VYGRVoyager Therapeutics... | +0.46 | +4.44% |
Data as of 4:00pm ET, 08/05/2020
Financials
| Last reporting date | August 5, 2020 |
| EPS forecast (this quarter) | -$0.54 |
| Annual revenue (last year) | $31.1M |
| Annual profit (last year) | -$55.2M |
| Net profit margin | -177.15% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Utrecht, Utrecht |
Forecasts
